IDH2 and acute myeloid leukemia: Enasidenib/CC‐90009 combination treatment reduced CD45+ malignant populations and increased differentiated CD14+ cells, indicating that the combination of CC‐90009 and mutant IDH2 inhibitor can overcome the problem of AML differentiation blockade.[123]